Coticchia Christine M, Yang Jiang, Moses Marsha A
Children's Hospital Boston, Boston, MA 02115, USA.
J Natl Compr Canc Netw. 2008 Sep;6(8):795-802. doi: 10.6004/jnccn.2008.0059.
As more effective, less toxic cancer drugs reach patients, the need for accurate and reliable cancer diagnostics and prognostics has become widely appreciated. Nowhere is this need more dire than in ovarian cancer; here most women are diagnosed late in disease progression. The ability to sensitively and specifically predict the presence of early disease and its status, stage, and associated therapeutic efficacy has the potential to revolutionize ovarian cancer detection and treatment. This article reviews current ovarian cancer diagnostics and prognostics and potential biomarkers that are being studied and validated. Some of the most recent molecular approaches being used to identify genes and proteins are presented, which may represent the next generation of ovarian cancer diagnostics and prognostics.
随着更有效、毒性更小的癌症药物应用于患者，对准确可靠的癌症诊断和预后评估的需求已得到广泛认可。这种需求在卵巢癌中最为迫切；在此类癌症中，大多数女性在疾病进展后期才被诊断出来。灵敏且特异地预测早期疾病的存在及其状态、分期和相关治疗效果的能力，有可能彻底改变卵巢癌的检测和治疗方式。本文综述了当前卵巢癌的诊断和预后评估方法以及正在研究和验证的潜在生物标志物。文中介绍了一些用于识别基因和蛋白质的最新分子方法，这些方法可能代表了下一代卵巢癌诊断和预后评估手段。
